Search

Displaying results 2091 - 2100 of 6076 in total
  1. Drug

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

    go.drugbank.com/drugs/DB10991
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus that infects the mucosal la...

    Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTION
  2. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.

  3. Drug

    Poly(lactic acid)

    go.drugbank.com/drugs/DB15037
    ApprovedInvestigationalWithdrawn

    Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).

  4. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.

  5. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups.

  6. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes. … Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada.

  7. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

  9. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).

  10. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not been sufficiently shown. … The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.